XNK Therapeutics to use generic name evencaleucel for lead candidate |
| September 26, 2022 | September 2022 Bond Updates |
|
HUDDINGE, Sweden, Sept. 26, 2022 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced it will adopt the generic name evencaleucel for its lead candidate targeting multiple myeloma. Evencaleucel was recently recommended by the World Health Organization (WHO) as the International... |
| View more at: https://www.prnewswire.com:443/news-releases/xnk-therapeutics-to-use-generic-name-evencaleucel-for-lead-candidate-301632787.html |
| Related News |